New insider activity at Zenas BioPharma, Inc. ( (ZBIO) ) has taken place on October 14, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Zenas BioPharma, Inc. stock, Director Patrick Enright acquired 117,255 shares valued at $2,250,026, while Director Jason Raleigh Nunn purchased 63,158 shares for $1,200,002. Additionally, significant shareholder SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares, amounting to $2,399,985.
Recent Updates on ZBIO stock
In the last 24 hours, Zenas BioPharma, Inc. has made significant strides with a licensing agreement with InnoCare Pharma, granting them exclusive rights to develop and commercialize orelabrutinib, a BTK inhibitor for multiple sclerosis, and other compounds. This strategic move aligns with Zenas’s expansion in the autoimmune treatment market, with a Phase 3 trial for orelabrutinib already underway. Additionally, Zenas announced a private placement expected to raise approximately $120 million, which will support its operations into 2027. These developments have influenced analysts’ perspectives, with some maintaining a neutral stance due to Zenas’s financial challenges, despite positive technical momentum and strategic funding efforts enhancing the commercial potential of its pipeline, particularly obexelimab.
Spark’s Take on ZBIO Stock
According to Spark, TipRanks’ AI Analyst, ZBIO is a Neutral.
Zenas BioPharma’s overall stock score is primarily impacted by its weak financial performance due to declining revenues and persistent losses. While the technical analysis shows positive momentum, the negative valuation metrics, including a negative P/E ratio, highlight significant financial challenges. The absence of earnings call insights and corporate events leaves the financial and technical aspects as the primary drivers of the score.
To see Spark’s full report on ZBIO stock, click here.
More about Zenas BioPharma, Inc.
YTD Price Performance: 194.56%
Average Trading Volume: 241,695
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.12B